Logo Logo
Hilfe
Hilfe
Switch Language to English

Schönhoff, Mirjam; Weineck, Gabriele; Hoppe, Julia; Hornig, Rinke; Cordts, Kathrin; Atzler, Dorothee; Gerloff, Christian; Boeger, Rainer; Neu, Axel; Schwedhelm, Edzard und Choe, Chi-Un (2018): Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks. In: Journal of Clinical Neuroscience, Bd. 50: S. 237-241

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

L-homoarginine (L-hArg) is an endogenous non-proteinogenic amino acid. Low L-hArg concentrations are associated with increased all-cause mortality, fatal strokes, and worse outcome after stroke. On the other hand, oral supplementation with L-hArg in mice improved neurological deficits and preserved cardiac function in experimental models of stroke and heart failure, respectively. Recently, oral supplementation with 125 mg daily L-hArg capsules in healthy volunteers demonstrated increased L-hArg plasma levels. Therefore, oral L-hArg supplementation could represent a potential treatment for patients with cerebrovascular disease. In addition to vascular physiology, animal studies have suggested that L-hArg might play a role in synapse function, neurotransmitter metabolism and cognitive training. However the direct influence of L-hArg on cognitive function has not been studied so far. In this study, cognitive performance in healthy humans was analyzed concerning memory, learning, and attention following supplementation with placebo or L-hArg for 4 weeks. Our results did not reveal any effects on cognition, neither impairment nor improvement, upon L-hArg supplementation. Therefore, potential L-hArg treatment is not expected to cause any acute neurocognitive or behavioral side effects.

Dokument bearbeiten Dokument bearbeiten